📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
5 articles
AVG GRADE
NEUTRAL
score: 0.10
SENTIMENT
BULLISH
TOTAL VIEWS
17
INMB Stock Analysis & AI Grade: NEUTRAL
5 articles analyzed · Sentiment: BULLISH · AI-powered equity research
RECENT COVERAGE · 7 ARTICLES
INmune Bio targets Ebstrocel U.K. MAA by end of Q3 or early Q4 2026 while outlining $1M-$1.5M monthly burn (NASDAQ:INMB)
INMB provided a regulatory timeline update targeting UK MAA (Marketing Authorization Application) for Ebstrocel by end-Q3 or early-Q4...
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INMB's Q2 2026 earnings call represents a standard quarterly reporting event for the biopharmaceutical sector. The company's financial...
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
INMB announced receipt of approximately $4.6 million in combined R&D tax rebates from Australia ($4.2M) and the United Kingdom ($0.4M),...
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
INmune Bio Inc. (INMB) announced a scheduled earnings report and corporate update for Q2 2026 results on August 6th. The announcement...
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
INmune Bio has formalized a Scientific Advisory Board focused on mesenchymal stem cell (MSC) clinical translation, a procedural...
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
INmune Bio has achieved a significant operational inflection by completing its commercial manufacturing milestone for the CORDStrom...
Oxford Brain Diagnostics Advances Vision for Measuring Brain Health and Neurodegenerative Disease with Five New Studies at AAIC 2026
Oxford Brain Diagnostics (INMB subsidiary) has released five new clinical studies demonstrating validation of its Cortical Disarray...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice